Physicians' Academy for Cardiovascular Education

ESC 2019

PACE-CME.org was present at the ESC 2019 in Paris, France. Find coverage of the latest CV news on PACE-CME.

Smartphone-based AF screening in the general population

5' education - Oct. 28, 2019 - Paris, France - Tine Proesmans

Hs-troponin measured 30 min after admission to diagnose MI

5' education - Oct. 24, 2019 - Paris, France - Camilla Bang, MD

Biochemical urine test to measure medical adherence in hypertension

5' education - Oct. 24, 2019 - Paris, France - Dan Lane

What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?

5' education - Oct. 23, 2019 - Paris, France - Prof. François Mach, MD

Betablocker use associated with reduced mortality in HFrEF patients >80 years

5' education - Oct. 22, 2019 - Paris, France - Gianluigi Savarese, MD

Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients

3' education - Oct. 21, 2019 - Prof. Freek Verheugt, Amsterdam - ESC 2019, Paris

Sex-related differences in ACS patients

5' education - Oct. 15, 2019 - Paris, France - Sanne Peters, PhD

NP metabolism associated with clinical outcomes in HF

5' education - Oct. 15, 2019 - Frank Gommans, MD, PhD

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD

CRP levels associated with risk of cancer in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Cilie van ’t Klooster, MD

Estimating individual lifetime benefit and bleeding risk with NOAC addition to asprin in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Tamar de Vries, MD

CVD in women

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Cecilia Linde - ESC 2019, Paris

What is mendelian randomization?

5' education - Oct. 10, 2019 - Paris, France - Prof. Børge Nordestgaard

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

No improved clinical outcomes with remote ischemic conditioning in STEMI patients undergoing PCI

3' education - Oct. 7, 2019 - Prof. Hans Erik Botker - ESC 2019, Paris

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

Reduced long-term CV death and MI with complete multivessel revascularization in STEMI

3' education - Sep. 25, 2019 - Paris, France - Prof. Shamir Mehta

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

No beneficial effects of oxygen use in subjects with a heart attack

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Ralph Stewart, New Zealand

Decreased CV risk with an intervention targeting identified barriers to care

3' education - Aug. 31, 2019 - ESC 2019, Paris - Prof. J-D Schwalm

Almost significant effects on CV outcomes with ARNI in HFpEF

3' education - Sep. 23, 2019 - Paris, France - Prof. Dirk Jan van Veldhuisen, MD

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein

The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society

5' education - Sep. 12, 2019 - Prof. Alberico Catapano

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg

Large community-based studies stress the impact of preventive measures

3' education - Sep. 9, 2019 - Paris, France - Prof. Salim Yusuf

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Importance of continuous use of secondary prevention therapy after CABG

3' education - Sep. 3, 2019 - Erik Björklund

A one-hour hs-troponin protocol in ACS suspected patients resulted in more rapid discharge

3' education - Sep. 3, 2019 - Prof. Derek Chew

Reduction in bleeding with genotype-guided strategy for choice of P2Y12i in STEMI patients

3' education - Sep. 3, 2019 - Danny Claassens

All-cause mortality benefit with ICD use in STEMI patients treated with primary PCI

3' education - Sep. 3, 2019 - Danielle Haanschoten

Smartphone-based AF screening in the general population

5' education - Oct. 28, 2019 - Paris, France - Tine Proesmans
Tine Proesmans explains how screening for AF can be done in the general population using a smartphone and shares results of the DIGITAL-AF II study.

CSI Paris Tine Proesmans explains how screening for AF can be done in the general population using a smartphone and shares results of the DIGITAL-AF II study.

Hs-troponin measured 30 min after admission to diagnose MI

5' education - Oct. 24, 2019 - Paris, France - Camilla Bang, MD
Camilla Bang shares preliminary results of her study on applying high-sensitive troponin results measured 30 minutes after admission to rule in or rule out acute MI in individuals with chest pain.

CSI Paris Camilla Bang shares preliminary results of her study on applying high-sensitive troponin results measured 30 minutes after admission to rule in or rule out acute MI in individuals with chest pain.

Biochemical urine test to measure medical adherence in hypertension

5' education - Oct. 24, 2019 - Paris, France - Dan Lane
Eline Groenland asks Dan Lane about his novel screening method using urine samples that can detect whether hypertensive patients take their drugs. This test may help to improve medical adherence.

CSI Paris Eline Groenland asks Dan Lane about his novel screening method using urine samples that can detect whether hypertensive patients take their drugs. This test may help to improve medical adherence.

What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?

5' education - Oct. 23, 2019 - Paris, France - Prof. François Mach, MD
Cilie van 't Klooster asks prof. Mach to summarize the most important changes in the 2019 ESC/EAS dyslipidemia guidelines.

CSI Paris Cilie van 't Klooster asks prof. Mach to summarize the most important changes in the 2019 ESC/EAS dyslipidemia guidelines.

Betablocker use associated with reduced mortality in HFrEF patients >80 years

5' education - Oct. 22, 2019 - Paris, France - Gianluigi Savarese, MD
Gianluigi Savarese tells about his study using data of the SwedeHF registry on the associations between use of betablockers and all-cause and CV mortality in HFrEF patients aged >80 years.

CSI Paris Gianluigi Savarese tells about his study using data of the SwedeHF registry on the associations between use of betablockers and all-cause and CV mortality in HFrEF patients aged >80 years.

Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients

3' education - Oct. 21, 2019 - Prof. Freek Verheugt, Amsterdam - ESC 2019, Paris
Prof.Freek Verheugt discusses the results of ISAR-REACT 5 in the broader context of the search for the best treatment for patients with CV disease.

ESC 2019 Prof.Freek Verheugt discusses the results of ISAR-REACT 5 in the broader context of the search for the best treatment for patients with CV disease.

Sex-related differences in ACS patients

5' education - Oct. 15, 2019 - Paris, France - Sanne Peters, PhD
Sanne Peters and Tamar de Vries talk about differences in impact of CV risk factors in women and men, and they highlight the need for awareness of sex-related differences in treatment effects.

CSI Paris Sanne Peters and Tamar de Vries talk about differences in impact of CV risk factors in women and men, and they highlight the need for awareness of sex-related differences in treatment effects.

NP metabolism associated with clinical outcomes in HF

5' education - Oct. 15, 2019 - Frank Gommans, MD, PhD
Frank Gommans presents a study on the association between levels of corin and neprilysin, enzymes involved in the metabolism of natriuretic peptides, and clinical outcomes in HF patients.

ESC 2019 Frank Gommans presents a study on the association between levels of corin and neprilysin, enzymes involved in the metabolism of natriuretic peptides, and clinical outcomes in HF patients.

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD
Jan Westerink tells about an exploratory analysis of the Look AHEAD trial, using a new prediction model to assess heterogeneity of treatment effects of an intensive lifestyle intervention on occurence of CV events in T2DM.

CSI Paris Jan Westerink tells about an exploratory analysis of the Look AHEAD trial, using a new prediction model to assess heterogeneity of treatment effects of an intensive lifestyle intervention on occurence of CV events in T2DM.

CRP levels associated with risk of cancer in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Cilie van ’t Klooster, MD
Steven Hageman asks Cilie van 't Klooster about her study on the relationship between CRP levels and risk of incident cancer and recurrent CV events in subjects with stable CVD in the SMART-cohort.

CSI Paris Steven Hageman asks Cilie van 't Klooster about her study on the relationship between CRP levels and risk of incident cancer and recurrent CV events in subjects with stable CVD in the SMART-cohort.

Estimating individual lifetime benefit and bleeding risk with NOAC addition to asprin in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Tamar de Vries, MD
Eline Groenland interviews Tamar de Vries on lifetime models that can be used to estimate individual benefit and bleeding risk with addition of low-dose rivaroxaban to aspirin therapy in subjects with stable CVD.

CSI Paris Eline Groenland interviews Tamar de Vries on lifetime models that can be used to estimate individual benefit and bleeding risk with addition of low-dose rivaroxaban to aspirin therapy in subjects with stable CVD.

CVD in women

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Cecilia Linde - ESC 2019, Paris
Prof. Cecilia Linde emphasizes known aspects of CVD in women, talks about the role of gender of the physician in outcomes of female patients and about the need for research of CVD in women.

ESC 2019 Prof. Cecilia Linde emphasizes known aspects of CVD in women, talks about the role of gender of the physician in outcomes of female patients and about the need for research of CVD in women.

ESC 2019
ESC 2019
ESC 2019